Short answer: FDA cosmetic adverse-event reports can help readers locate reports and notice questions worth checking. They do not show that a named shampoo, hair dye or smoothing product caused a reaction, and they cannot be used to calculate how often a reaction occurs. The FDA’s current Adverse Event Monitoring System (AEMS) brings public adverse-event access into a unified dashboard. Reports can be duplicated, incomplete and unverified; the agency says the data alone are not a product safety profile.
What changed in the FDA dashboard?
On March 11, 2026, FDA announced AEMS as a unified platform for adverse-event reports across regulated product areas, including cosmetics. FDA’s AEMS page describes the public dashboard as a searchable interface for reports submitted by industry, health professionals and consumers. FDA’s 2025 cosmetics-dashboard announcement described reports that included serious adverse events submitted by responsible persons under the Modernization of Cosmetics Regulation Act (MoCRA), together with voluntary submissions from consumers, salon professionals and others. The interface and historical data migration can change, so use the current FDA dashboard and record when you searched.
Older FDA cosmetic FAQ material still explains the limitations of cosmetic reports and how the earlier FAERS dashboard worked. Treat those instructions as background for interpreting reported data; do not assume every screen label or filter is unchanged in AEMS.
A careful way to search a hair-product report
- Start with the exact identity. Record the product name as printed, manufacturer or responsible person, product type, market, package size, and any formula or shade variant. “Keratin treatment,” “hair dye,” or a brand family is too broad to establish a product match.
- Keep the query reproducible. Note the search terms, selected filters, date range, and access date. Save a link or screenshot for your own records where permitted. A real-time dashboard may change after new submissions or corrections.
- Read the report as an allegation or observation. Capture what the reporter says happened, the reported reaction, product and timing details, and what is missing. A report may involve other products, a medical condition, or incomplete identity information.
- Check case versions and duplicates. FDA’s legacy cosmetics FAQ explains that follow-up information can create later versions of a case and that duplicate submissions may occur. Do not add every row as a separate person or event without checking the dashboard’s case identifiers and version fields.
- Look for a separate regulatory action. A dashboard report is not a recall, warning letter, or FDA finding. Search FDA recalls, safety alerts, warning letters, and product-specific notices separately before describing an official action.
Four conclusions the report count cannot support
- “The product caused the reaction.” FDA says reports have not necessarily been verified and do not establish causation.
- “Product A is safer than product B because it has fewer reports.” People do not report every event; awareness, sales duration, reporting routes, media attention and serious-event obligations differ.
- “There is a one-in-N chance of a reaction.” Reports lack a reliable denominator of users and are not a representative sample. FDA expressly says the data cannot establish incidence or a safety profile.
- “No search result means no problem.” A missing result can reflect a different name, spelling, product category, reporting period, incomplete submission or an event that was never reported.
Mandatory and voluntary reports are not the same stream
MoCRA requires the responsible person for a cosmetic product to submit certain serious adverse-event reports received about the product. Other reports may be voluntary, including reports from consumers and health professionals. A higher count can therefore reflect differences in product exposure, time on the market, reporting behaviour, follow-up or reporting route—not a direct comparison of risk. Before drawing a trend, ask whether the same product identity, period, severity definition and reporting pathway were used.
A compact evidence note for readers and editors
| Field | Record |
|---|---|
| Source and access date | FDA AEMS dashboard; date and time checked |
| Product identity | Exact name, type, manufacturer/responsible person, variant and market |
| Query design | Search terms, filters and date window; distinguish case ID from case version |
| What the report says | Reported event and timeline, with attribution to the reporter |
| What remains unknown | Causation, full medical context, total users, under-reporting and unreported events |
| Independent status check | Separate FDA recall, alert, warning letter or other official action, if any |
When a customer reports a reaction
A dashboard is not a triage tool. A person experiencing a serious or worsening reaction should seek appropriate medical care and contact the product’s responsible person or the FDA through its current reporting instructions. Preserve the product label, lot or batch, purchase record and use timeline if doing so is practical. Do not infer an individual diagnosis or tell someone to continue using a product based on a report count.
Frequently asked questions
Does FDA approve every cosmetic before sale?
No. FDA’s cosmetic oversight framework differs from premarket approval for many drugs. The dashboard is post-market reporting information; its presence does not convert a cosmetic into an FDA-approved product.
Can I compare adverse-event counts between hair dyes?
You can compare what was reported only if you clearly define matching product identities and comparable periods. You cannot turn those raw counts into relative safety rates because the number of exposed users and reporting completeness are unknown.
Is the old FAERS cosmetics page still the right place?
FDA announced AEMS in March 2026 and currently directs users to its AEMS public dashboard. Use FDA’s current entry point; treat older cosmetics FAQ pages as supporting guidance unless FDA updates or redirects them.
Sources and scope
Checked 2 October 2026. This U.S.-focused explainer interprets FDA materials; it does not review a named product’s dashboard records, establish product safety, provide medical advice, or represent an FDA conclusion.
FDA — AEMS overview and data limitations · FDA — AEMS launch, 11 March 2026 · FDA — Cosmetic dashboard and report scope · FDA — Cosmetic adverse-event dashboard FAQ
Leave a Reply